Who is a migrant? 12/10/2018. HIV and migrants. Heterogeneous groups of persons with different migration drivers

Similar documents
ECDC and Spanish Ministry of Health workshop:

Monthly measles and rubella monitoring report

Smokefree Policies in Europe: Are we there yet?

WCPT COUNTRY PROFILE December 2017 SWEDEN

WCPT COUNTRY PROFILE December 2017 HUNGARY

WCPT COUNTRY PROFILE December 2017 SERBIA

Syphilis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

Table 7.1 Summary information for lung cancer in Ireland,

Cross Border Genetic Testing for Rare Diseases

Yersiniosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods. Epidemiology

Shigellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

Access to treatment and disease burden

Trichinellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

Overview of drug-induced deaths in Europe - What does the data tell us?

Tuberculosis Now! Jon S Friedland MA, FRCPE, FMedSci. Infectious Diseases & Immunity

Table 9.1 Summary information for stomach cancer in Ireland,

Key issues for HIV testing and

A phylodynamic analysis of HIV-1 in Germany

Lymphogranuloma venereum

The epidemiology of HIV and AIDS reports in migrants in the 27 European Union countries, Norway and Iceland:

Biology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

LEBANON. WCPT COUNTRY PROFILE December 2018

11 Melanoma of the skin

Hepatitis A SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

DENMARK. WCPT COUNTRY PROFILE December 2018

Reflecting on ten years of progress in the fight against AIDS, TB and malaria

GERMANY. WCPT COUNTRY PROFILE December 2018

Table 6.1 Summary information for colorectal cancer in Ireland,

ECDC s role in the fight against HIV/AIDS in Europe

PARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information

Rheumatoid Arthritis Disease Burden and Access to Treatment

Burden and cost of alcohol, tobacco and illegal drugs globally and in Europe

UK bowel cancer care outcomes: A comparison with Europe

Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS

Where we stand in EFORT

European Collaboration on Dementia. Luxembourg, 13 December 2006

Measles and rubella monitoring January 2015

Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

ALCOHOL CONSUMPTION IN EUROPE; TRADITIONS, GENERATIONS, CULTURE AND POLICY

The health economic landscape of cancer in Europe

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Alcohol Prevention Day

Monitoraggio delle epatiti virali in Europa

Engagement in language assessment / Regions of Europe

European Status report on Alcohol and Health

Cascade of care among migrants in Belgium and in Europe. Dr Rémy Demeester Aids Reference Centre of Charleroi 24th of November 2017 BREACH Symposium

Where do EU Contries set the limit for low risk drinking.

Drinking guidelines used in the context of early identification and brief interventions in Europe: overview of RARHA survey results

Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

Weekly influenza surveillance overview

The current status of PrEP in Europe. Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint

TEDDY. Teddy Network of Excellence. Annagrazia ALTAVILLA. Ph.D. Sciences Ethics LL.M. Health Law. diterranée

Media Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences

Injecting trends in Austria including results of a systematic literature review on interventions aiming to influence the route of administration

HIV transmission in the migrant population. D. Paraskevis

The cancer burden in the European Union and the European Region: the current situation and a way forward

Cost of Disorders of the Brain in Europe Gustavsson et al. Cost of disorders of the brain in Europe Eur. Neuropsych. (2011) 21,

Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke

Q1 What age are you?

Alcohol-related harm in Europe and the WHO policy response

National Institute on Alcohol Abuse and Alcoholism. Environmental Approaches

ECDC update to the EU Commission Think Tank on HIV/AIDS

31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million

Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area

Molecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA

Epidemiology of tuberculosis in Europe. Marieke J. van der Werf European Centre for Disease Prevention and Control Amsterdam, 22 September 2014

Current levels and recent trends in health inequalities in the EU: Updates from the EU Report

Estimating Smoking Related Cause of Death: a Cohort Approach Based on Lung Cancer Mortality in six European Countries

10/07/18. Dr. Otilia Mårdh, ECDC. No conflicts of interest.

Giardiasis (lambliasis)

Invasive meningococal diseasefocus on Meningococcal B - epidemiology, international and Ireland

Underage drinking in Europe

European monthly measles monitoring (EMMO)

Men & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013

PRESS RELEASE ISSUED BY THE STATE UNIVERSITY OF NEW YORK AT ALBANY

Research paper: Legal treatment of the use of cannabis for medical purposes in the member states of the European Union

508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender

Identifying Europe s information needs for effective drug policy Lisbon, EMCCDA

VIRUS VACCINES & CANCER a story with two chapters

A report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 20% 10%

Implementing the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2010 Progress Report SPECIAL REPORT.

Project Meeting Prague

Department of Biological Standardisation OMCL Network & Healthcare (DBO)

AFRICAN AND BLACK DIASPORA GLOBAL NETWORK ON HIV AND AIDS ABDGN AIDS 2012 HIGHLIGHTS

The Risk of Alcohol in Europe. Bridging the Gap June 2004

Molecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA

Nutrient profiles for foods bearing claims

Outcome of proficiency test on EIA serology

Program to control HIV/AIDS

HIV/AIDS Joint Action HA-REACT

Overall survival: 1 st line therapy

Transcription:

HIV and migrants Julia del Amo has received research grants awarded to her institution from Companies BMS, Gilead, ViiV and epidemiology teaching fees from ViiV, Gilead and MSD Dr Julia del Amo National Center for Epidemiology Institute of Health Carlos III Madrid, Spain Heterogeneous groups of persons with different migration drivers Heterogeneous Migrants and mobile groups populations of persons are any with person different who is moving migration or has moved across an international drivers border or within a State away from his/her habitual place of residence, regardless of: (1) The persons legal status (2) Whether the movement is voluntary or involuntary (3) What the causes for the movement are; or (4) What the length of stay is UNAIDS definition for the report People on the Move Distinct risk-contexts for HIV infections 1

Proportion HIV diagnoses in migrants* by country of report, EU/EEA 2016 40% Sweden Malta Ireland Luxembourg Belgium Norway United Kingdom Iceland France Finland Denmark Cyprus Austria EU/EEA Average Netherlands Germany Italy Spain Portugal Czech Republic Greece Slovenia Croatia Estonia Slovakia Bulgaria Lithuania Latvia Poland Sub Saharan Africa Central and Eastern Europe Western Europe Latin America and Caribbean South and Southeast Asia Other 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Percentage of new diagnoses New HIV diagnoses, by year of diagnosis, transmission and migration status, EU/EEA, 2007 2016 Migrant MSM Heterosexual migrants Migrant IDU Data is adjusted for reporting delay 10 New HIV diagnoses, by year of diagnosis, transmission and migration status, EU/EEA, 2007 2016 7000 Number of diagnoses 6000 5000 4000 3000 2000 2% 36% 9% +58% 1000 0 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Year of diagnosis MSM (born in reporting country) Heterosexual (born in reporting country) MSM (foreign born) Heterosexual (foreign born) 2

HIV epidemics in migrants from Latin America & Caribbean in Europe are driven by MSM TUPEC190 53% of the HIV reports from LAC 2004 2015 were MSM; 84% of reports from South America to 46% of reports from the Caribbean Unknown region SA men Andean men MSM from all sub regions consistently show higher CD4 counts at HIV diagnosis HIV dynamics in migrants from Central, Eastern and Western Europe in the Europe Union/Economic Area (EU/EEA) THPEC174 In Western, Central and Eastern European migrants, 74%, 57% and 26% of the HIV reports MSM WE men CE men Those driving HIV in countries of origin Factors underlying high rates of HIV infection Risk behaviors and risk contexts during migration transit MSM from all sub regions consistently show higher CD4 counts at HIV diagnosis Risk behaviors and risk contexts in countries of destination amase Pre and post-migration HIV acquisition CASCADE: repeated mesurements that allow to estimate trends in CD4 and VL after seroconversion. CD4 VL AIDS Sociodemographic characteristics Stat Methods Med Res December 2017 HIV acquisition HIV Diagnosis Before or after migration? 3

2249 migrants living with HIV 68% men 46% MSM 36 years median age Geographical origin Western Central Eastern SSA LA & Asia Caribbean 11% 10% 5% 33% 31% 5% Other 5% MSM were more likely to Approx 72% of migrant MSM and 50% heterosexual migrants from SSA acquired HIV post migration Estimated post migration HIV acquisition probability (95% CI) by country of destination To be single To have stable residency status To have higher education & income Higher socio-economic status than heterosexuals and PWID Barriers to access testing and care in migrants Location of barriers Structural Barriers Healthcare act in synergy limiting access Community to, levels or acceptance of, HIV testing, treatment uptake and responses Nature of barriers Socio-economic inequalities Legal Stigma and discrimination Cultural & linguistic & gender Psychological low risk perception They undermines public health Homophobia approaches for HIV control 4

Availability of ART for undocumented migrants, 2018 Status of formal PrEP implementation in Europe July, 2018 Source: ECDC. From Dublin to Rome: ten years of responding to HIV in Europe and Central Asia: Stockholm, ECDC; 2014 Source: ECDC. Dublin Declaration monitoring 2018; validated unpublished data. Source: ECDC. Dublin Declaration monitoring 2018; validated unpublished data. HIV challenges for migrant populations Better understanding of HIV transmission dynamics at local level Global & inclusive HIV prevention and treatment strategies in origin & destination Increase HIV&STI testing & linkage to care PrEP & comprehensive STIs approaches Universal access to ART in Europe including PrEP Thank you 5